Vendor, Cambridge, MA
Spero Therapeutics, Inc.
UEI NX34PL7NZW24, CAGE 7SK81
2 awards and $20,944,972 obligated between July 3, 2024 and July 20, 2026, 100% under full and open competition, against 12.0 offers on average where reported.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | $17,520,435 |
| National Institutes of Health | $3,424,537 |
Industries
NAICS on the awards, by dollars.
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
| Definitive Contract | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50118C00015Definitive Contract, July 3, 2024, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Modification P00015 the Purpose of This Bilateral Modification Is To: A) Increase the US Government Funding for Clin 0005 Option 4 from $12,NAICS 541714, PSC AN13 | $17,520,435 |
| 75N93021C00022Definitive Contract, July 11, 2024, Full and Open Competition, 23 offers | National Institutes of Health NiaidNational Institutes of Health | To Advance Clinical and Non-Clinical Development of an Antibiotic Candidate.NAICS 541715, PSC AN11 | $3,424,537 |
- Places of performance
- Massachusetts
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental DevelopmentAN11 Health R&D Services; Health Care Services; Basic Research
- Transactions
- 13 across 2 awards